Skip to main content
SpringerLink
Log in

Approval of bevacizumab (Avastin) for use in metastatic breast cancer (mBC) has been suspended

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Health Canada.Avastin (bevacizumab) - Health Canada has Suspended Approval for Use in Metastatic Breast Cancer - For Health Professionals. Internet Document: 29 Nov 2011. Available from: URL: http://www.hc-sc.gc.ca

  2. Health Canada.Health Canada directs Hoffmann-La Roche to remove use of Avastin (bevacizumab) for the treatment of metastatic breast cancer from the product label. Media Release: 28 Nov 2011. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Approval of bevacizumab (Avastin) for use in metastatic breast cancer (mBC) has been suspended. React. Wkly. 1381, 4 (2011). https://doi.org/10.2165/00128415-201113810-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113810-00007

Keywords

Search

Navigation